Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 6:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 66 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Mononuclear cell collection. Clear all
Completed Phase 1 Interventional

CD19-specific T-cell for Chronic Lymphocytic Leukemia (CLL)

NCT01653717
View directory record Official record
Conditions
Advanced Cancers, Leukemia
Interventions
Leukapheresis, Fludarabine, Cyclophosphamide, T-cell Infusion
Procedure · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 16, 2017 · Synced Sep 2, 2026, 6:45 AM EDT
Suspended No phase listed Observational

Paclitaxel Therapeutic Drug Monitoring in Cancer Patients

NCT03987555
View directory record Official record
Conditions
Solid Tumor, Adult, Metastatic Nonsmall Cell Lung Cancer, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Cervical Carcinoma, Metastatic Ovarian Carcinoma, Malignant Uterine Neoplasm, Vulvar Cancer, Invasive Breast Cancer, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8, Recurrent Breast Carcinoma, Recurrent Cervical Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Vulvar Carcinoma, Stage IV Cervical Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Vulvar Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IVA Cervical Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVA Vulvar Cancer AJCC v8, Stage IVB Cervical Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8, Stage IVB Vulvar Cancer AJCC v8, Vulva Squamous Cell Carcinoma
Interventions
Blood draws, QLQ-CIPN20 Survey, PR-CTCAE Survey
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 2, 2026, 6:45 AM EDT
Not yet recruiting No phase listed Observational

Radiation Therapy and Thymus Function in Young Women With Breast Cancer

NCT07725172
View directory record Official record
Conditions
Breast Cancer
Interventions
Blood draw for the laboratory assessment
Procedure
Lead sponsor
Duke University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 2, 2026, 6:45 AM EDT
Not listed Phase 2Phase 3 Interventional

Clinical Application of Stem Cell Educator Therapy in Type 1 Diabetes

NCT04011020
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Stem Cell Educator therapy
Combination Product
Lead sponsor
Throne Biotechnologies Inc.
Industry
Eligibility
14 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Hackensack, New Jersey • Paramus, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 28, 2024 · Synced Sep 2, 2026, 6:45 AM EDT
Completed Phase 1 Interventional

Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple Myeloma

NCT02655458
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Elotuzumab, Lenalidomide, autologous PBMC reconstitution, ASCT
Drug · Other
Lead sponsor
Hearn Jay Cho
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 17, 2017 · Synced Sep 2, 2026, 6:45 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Evaluation of the Spectra Optia® Apheresis System Mononuclear Cell (MNC) Collection Procedure in Healthy Blood Donors

NCT01277549
View directory record Official record
Conditions
Leukapheresis
Interventions
Mononuclear cell collection.
Device
Lead sponsor
Terumo BCT
Industry
Eligibility
18 Years to 50 Years
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
3
States / cities
Emeryville, California • Memphis, Tennessee • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 2, 2013 · Synced Sep 2, 2026, 6:45 AM EDT
Terminated No phase listed Observational

Bioenergetic Profiling and Cognition in GBM Patients

NCT03939858
View directory record Official record
Conditions
Glioblastoma
Interventions
Cognitive Assessment, Blood Collection, Bioenergetic Profiling
Procedure · Diagnostic Test
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Sep 2, 2026, 6:45 AM EDT
Active, not recruiting No phase listed Observational

Evaluation of Intravenous Laronidase Pharmacokinetics Before and After Hematopoietic Cell Transplantation in Patients With Mucopolysaccharidosis Type IH.

NCT05634512
View directory record Official record
Conditions
Hematopoietic Cell Transplantation, Mucopolysaccharidosis Type I
Interventions
Laronidase therapy and a stem cell transplant
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
0 Years to 3 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Sep 2, 2026, 6:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

An Evaluation of the Spectra Optia CMNC Collection Procedure

NCT02253160
View directory record Official record
Conditions
Healthy Apheresis Donors, Mononuclear (MNC) Cell Donors
Interventions
Spectra Optia CMNC, COBE Spectra MNC, Granulocyte-colony stimulating factor (G-CSF)
Device · Drug
Lead sponsor
Terumo BCT
Industry
Eligibility
18 Years to 50 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
2
States / cities
Cincinnati, Ohio • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 23, 2015 · Synced Sep 2, 2026, 6:45 AM EDT
Completed No phase listed Observational

Pilot Study Using Propranolol To Promote Prenylation Of Gtpase Rap1b In Hematopoietic Stem Cell Transplant Recipients

NCT02535182
View directory record Official record
Conditions
Hematopoietic Stem Cell Transplantation
Interventions
Blood Draw
Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 25, 2020 · Synced Sep 2, 2026, 6:45 AM EDT
Suspended Not applicable Interventional Accepts healthy volunteers

Changes in Cellular Immune Profile During COVID-19 Infection

NCT04470999
View directory record Official record
Conditions
Covid19, SARS-CoV-2
Interventions
Leukapheresis
Other
Lead sponsor
Serhat Gumrukcu, MD PhD
Other
Eligibility
18 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 23, 2022 · Synced Sep 2, 2026, 6:45 AM EDT
Active, not recruiting No phase listed Observational

Exploring Relevant Immune-based Biomarkers and Circulating Tumor Cells During Treatment With Immunotherapy in Genitourinary Malignancies (CTC Immune Based Biomarkers)

NCT02978118
View directory record Official record
Conditions
Carcinoma, Renal Cell, Carcinoma, Urothelial
Interventions
Immune cell and CTC detection procedures
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Sep 2, 2026, 6:45 AM EDT
Completed No phase listed Observational

Evaluating Dactinomycin and Vincristine in Young Patients With Cancer

NCT00674193
View directory record Official record
Conditions
Childhood Acute Lymphoblastic Leukemia, Childhood Rhabdomyosarcoma, Childhood Soft Tissue Sarcoma, Ewing Sarcoma, Ewing Sarcoma of Bone, Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor (PNET), Unspecified Childhood Solid Tumor, Protocol Specific, Wilms Tumor and Other Childhood Kidney Tumors
Interventions
pharmacological study, laboratory biomarker analysis
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 16 Years
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
36
States / cities
Birmingham, Alabama • Long Beach, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated May 16, 2017 · Synced Sep 2, 2026, 6:45 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Collection of Peripheral Blood Mononuclear Cells (PBMCs) From Healthy People for the Expansion of T Cells for Adoptive Cell Therapy

NCT02821806
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2035
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 2, 2026, 6:45 AM EDT
Terminated Phase 3 Interventional

S9901 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Men With Stage III or Stage IV Hodgkin's Disease

NCT00005090
View directory record Official record
Conditions
Lymphoma
Interventions
bleomycin sulfate, carmustine, cyclophosphamide, dacarbazine, doxorubicin hydrochloride, etoposide, vinblastine, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
15 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
47
States / cities
Birmingham, Alabama • La Jolla, California • San Francisco, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Sep 2, 2026, 6:45 AM EDT
Recruiting Phase 2 Interventional

Autologous Dendritic Cell Vaccine in Kidney Cancer

NCT05127824
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Autologous alpha-DC1/TBVA vaccine, Cabozantinib
Biological · Drug
Lead sponsor
Jodi Maranchie
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 2, 2026, 6:45 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Peripheral Blood Mononuclear Cells Response In Healthy Controls, Heavy Drinkers, and Patients With Alcoholic Hepatitis

NCT04088370
View directory record Official record
Conditions
Alcoholic Hepatitis
Interventions
Blood Draw
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
21 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Sep 2, 2026, 6:45 AM EDT
Recruiting Phase 1 Interventional

CARv3-TEAM-E T Cells in Glioblastoma

NCT05660369
View directory record Official record
Conditions
Glioblastoma, Malignant Glioma, Recurrent Glioblastoma, Recurrent Glioma
Interventions
CARv3-TEAM-E T cells
Drug
Lead sponsor
Marcela V. Maus, M.D.,Ph.D.
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Sep 2, 2026, 6:45 AM EDT
Terminated No phase listed Observational

Collection of Blood in Studying Metabolites in Patients With Prostate Cancer

NCT03485794
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Biospecimen Collection, Laboratory Biomarker Analysis
Procedure · Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Sep 2, 2026, 6:45 AM EDT
Active, not recruiting Phase 1 Interventional

Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies

NCT04732845
View directory record Official record
Conditions
Non Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia
Interventions
Fully human anti CD19 CAR-T Cell Dose, Fludarabine, Cyclophosphamide
Biological · Drug
Lead sponsor
Benjamin Tomlinson
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2039
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Sep 2, 2026, 6:45 AM EDT
Completed Phase 2 Interventional Results available

Docetaxel, Thalidomide, Prednisone, and Bevacizumab to Treat Metastatic Prostate Cancer

NCT00089609
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Docetaxel, Thalidomide, Prednisone, bevacizumab, polymorphism analysis, immunoenzyme technique, laboratory biomarker analysis, pharmacological study
Drug · Biological · Genetic + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 19, 2018 · Synced Sep 2, 2026, 6:45 AM EDT
Completed Phase 1 Interventional

Biological Therapy in Treating Women With Stage IV Breast Cancer

NCT00027807
View directory record Official record
Conditions
Breast Cancer
Interventions
Aldesleukin, Sargramostim, therapeutic autologous lymphocytes
Biological
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2013
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 16, 2016 · Synced Sep 2, 2026, 6:45 AM EDT
Completed No phase listed Observational

The Role of JAK2 in Alveolar Macrophages (AM's) in Chronic Beryllium Disease (CBD)

NCT02596347
View directory record Official record
Conditions
Chronic Beryllium Disease (CBD), Beryllium Sensitization (BeS)
Interventions
Blood draw, bronchoscopy
Procedure
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 18, 2020 · Synced Sep 2, 2026, 6:45 AM EDT
Terminated Not applicable Interventional Results available

Safety and Efficacy Study of Autologous Concentrated Bone Marrow Aspirate (cBMA) for Critical Limb Ischemia (CLI)

NCT01049919
View directory record Official record
Conditions
Critical Limb Ischemia, Peripheral Arterial Disease, Peripheral Vascular Disease
Interventions
Bone marrow concentration device, Placebo procedure (sham)
Device · Procedure
Lead sponsor
Zimmer Biomet
Industry
Eligibility
21 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
25
States / cities
Little Rock, Arkansas • Sacramento, California • Miami, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated May 27, 2021 · Synced Sep 2, 2026, 6:45 AM EDT